Related Experiment Videos
[Olanzapine-induced diabetes mellitus]
1Landesklinik Brandenburg, Germany.
Psychiatrische Praxis
|September 12, 2002
Abstract:
A potential side-effect in the treatment with olanzapine is hyperglycemia or new onset diabetes mellitus. There are possible mechanisms by which olanzapine could interfere with glucose metabolism but decreased insulin sensitivity due to weight gain is of most relevance.
Insights
Olanzapine treatment may lead to hyperglycemia and new-onset diabetes mellitus. Weight gain-induced insulin resistance is the most relevant mechanism for this metabolic side effect.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Disorders
Background:
- Olanzapine is an atypical antipsychotic medication used for treating schizophrenia and bipolar disorder.
- Metabolic side effects, including hyperglycemia and diabetes mellitus, are recognized risks associated with olanzapine therapy.
Observation:
- Clinical observations indicate a correlation between olanzapine use and the development of hyperglycemia.
- Patients treated with olanzapine exhibit an increased incidence of new-onset diabetes mellitus.
Findings:
- Weight gain is a common side effect of olanzapine, significantly contributing to metabolic disturbances.
- Decreased insulin sensitivity, primarily driven by olanzapine-induced weight gain, is identified as a key mechanism impacting glucose metabolism.
- Olanzapine may interfere with glucose homeostasis through various pathways, with insulin resistance being the most clinically relevant.
Implications:
- This highlights the importance of monitoring glucose levels and weight in patients undergoing olanzapine treatment.
- Understanding the mechanisms of olanzapine-induced hyperglycemia can inform preventative strategies and patient management.
- Further research into mitigating insulin resistance could improve the metabolic safety profile of olanzapine.